Levamisole in steroid dependent and frequently relapsing nephrotic syndrome

The prognosis for nephrotic syndrome under treatment is generally good although this depends on the underlying cause, the age of the patient and their response to treatment. It is usually good in children, because minimal change disease responds very well to steroids and does not cause chronic renal failure . Any relapses that occur become less frequent over time; [50] the opposite occurs with mesangiocapillary glomerulonephritis , in which the kidney fails within three years of the disease developing, making dialysis necessary and subsequent kidney transplant . [50] In addition children under the age of 5 generally have a poorer prognosis than prepubescents, as do adults older than 30 years of age as they have a greater risk of kidney failure. [51]

RESULTS: Among the 95 cases with FRNS (n=62) and SDNS (n=33) studied, alternate day levamisole therapy was efficacious in % (n=70). The overall efficacy of levamisole therapy was % (n=84). Levamisole therapy decreased the mean (SD) number of relapses from ()/year to ()/year (P<); and cumulative median (IQR) prednisolone dosage from 4200 (3200-4300) mg/m2 to 1100 (IQR 500-2900) mg/m2 (P<). Daily levamisole therapy as 'rescue therapy' was effective in 56% (n=14) of children who had demonstrated alternate day levamisole failure (n=25). On a one-year follow up of the cases in whom alternate day or daily levamisole therapy was efficacious during therapy (median 24 months) (n=84), a frequently relapsing or steroid dependent course continued to persist in % (n=41), necessitating oral cyclophosphamide (n= 22) or mycophenolate mofetil (n=19).

Through relationships with leading principals, suppliers and clients based on successful and trusting collaboration, TIEFENBACHER has the experience and ability to exceed the needs of the pharmaceutical and API industries. TIEFENBACHER as API Sourcer The power of networking Transparency in the relationship between the manufacturer, the commissioner and TIEFENBACHER is of paramount importance in delivering value to TIEFENBACHERs clients, and promotes trusting and open collaborations that are best able to innovate and be efficient in dealing with complex and challenging situations.

Levamisole in steroid dependent and frequently relapsing nephrotic syndrome

levamisole in steroid dependent and frequently relapsing nephrotic syndrome

Media:

levamisole in steroid dependent and frequently relapsing nephrotic syndromelevamisole in steroid dependent and frequently relapsing nephrotic syndromelevamisole in steroid dependent and frequently relapsing nephrotic syndromelevamisole in steroid dependent and frequently relapsing nephrotic syndromelevamisole in steroid dependent and frequently relapsing nephrotic syndrome